Global Embolization Therapy Market By Therapy Procedure (Radioembolization – Transarterial Radioembolization (TARE), Selective Internal Radiation Therapy (SIRT), Blandembolization, Chemoembolization); By Embolization agents (Organic, Coils, Plugs and Balloons, Beads and Particles, Suture Materials, Others); By Application (Hepatocellular Carcinoma, Neuroendocrine Tumor, Liver Cancer, Kidney Cancer, Breast Cancer Metastases, Uterine Fibroids, Others); By End User (Hospitals and Clinics, Specialty Clinics, Research Institutions, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global embolization therapy market was valued at US$ 3.4 Bn in 2021, growing at an estimated CAGR of 8.0% over the forecast period. The procedure of injecting substances directly in the artery, specifically the one in liver in order to block or bring down the amount of blood flow to the tumour in liver is known as embolization. The number of people affected with chronic diseases like cancer and this is driving the growth of embolization therapy market. The reason behind importance of liver is that it has not one but two blood supplies. While in majority of the cases, specifically the normal livers, the normal liver cells feed through the portal vein. On the other hand, the liver impacted with cancer is primarily fed through the hepatic artery.
The growth of the embolization therapy market was hindered by the recent coronavirus pandemic. People with cancer were at major risk from the COVID-19 infection. This is exactly why the diagnosis, screening along with the procedures that required surgery at hospitals and cancer centres were postponed. This took a toll on the business of this market.
Therapy Procedure Outlook
On the basis of therapy procedure, the embolization therapy market has been divided into radioembolization, biandembolization and chemoembolization. The radioembolization therapy procedure has been further segregated into transarterial radioembolization (TARE) and selective internal radiation therapy (SIRT). The transarterial radioembolization (TARE) procedure generates maximum revenue for this market. In this therapy procedure, a flexible tube which is thin called a catheter is planted into artery near inner thigh with the help of a small cut and then eased into the hepatic artery.
Global Embolization Therapy Market Revenue & Forecast, (US$ Million), 2022 – 2030
Embolization Agents Outlook
The embolization agents’ segment of the embolization therapy market has been segregated into organic, coils, plugs and balloons, beads and particles, suture materials, and others. The beads and particles segment dominates in terms of account share in the revenue generated by this market. The tiny beads containing chemotherapy drug is used in chemoembolization therapy.
Application Outlook
On the basis of application, the embolization therapy market has been bifurcated into hepatocellular carcinoma, neuroendocrine tumor, liver cancer, kidney cancer, breast cancer metastases, uterine fibroids and others. The hepatocellular carcinoma which happen to be microspheres are immensely contributing to the growth of this market, especially in countries that have great healthcare infrastructure in terms of better reimbursement criteria. The TACE and TARE procedures are extensively adopted due to rise in number of liver and kidney cancer patients.
End User Outlook
The end user segment of the embolization therapy market has been divided into hospitals and clinics, specialty clinics, research institutions, and others. The hospitals and clinics segment makes most of the money for this market. Surging adoption of invasive surgical procedures that are minimal in nature like neurological, vascular and urological contributes to this segment’s success along with upward going spending power of leading healthcare providers across developed economies.
Region Outlook
The region of North America dominated the embolization therapy market in terms of market share. The countries like the United States and Canada have better availability of reimbursements when it comes to target procedures like embolization. Also the fact, number of bigger hospitals, clinics and specialty clinics have gone up in the region, this too contributes to the growth of this market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global embolization therapy market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global embolization therapy market are listed below:
- ABK Biomedical Inc.
- Boston Scientific Corporation
- BTG International Limited
- Cook Medical
- EmboMedics
- IMBIOTECHNOLOGIES LTD.
- Johnson & Johnson Services Inc.
- Merit Medical Systems Inc.
- Radiology Imaging Associates
- Sirtex Medical Pty Ltd
- Stryker Corporation
- Terumo Corporation
- Other Market Participants
Global Embolization Therapy Market
By Therapy Procedure
- Radioembolization
- Transarterial Radioembolization (TARE)
- Selective Internal Radiation Therapy (TARE)
- Blandembolization
- Chemoembolization
By Embolization Agents
- Organic
- Coils
- Plugs and Balloons
- Beads and Particles
- Suture Materials
- Others
By Application
- Hepatocellular Carcinoma
- Neuroendocrine Tumor
- Liver Cancer
- Kidney Cancer
- Breast Cancer metastases
- Uterine Fibroids
- Others
By End Use
- Hospitals and Clinics
- Specialty Clinics
- Research Institutions
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Embolization Therapy Market
6.
Market
Synopsis: Embolization Therapy Market
7.
Embolization
Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Embolization Therapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Embolization Therapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Embolization Therapy
Market
8.
Global
Embolization Therapy Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Embolization Therapy Market Revenue
(US$ Mn)
8.2. Global Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapy Procedure
8.2.1. Radioembolization (Definition, Market
Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021),
Market Forecast (2022 – 2030), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Transarterial Radioembolization (TARE), Selective
Internal Radiation Therapy (TARE))
8.2.1.1.
Transarterial
Radioembolization (TARE)
8.2.1.2.
Selective
Internal Radiation Therapy (TARE)
8.2.2. Blandembolization
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 – 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Chemoembolization
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 – 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Therapy Procedure
9.
Global
Embolization Therapy Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Embolization Agents
9.2.1. Organic
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 – 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Coils
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 – 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Plugs and Balloons
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 – 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Beads and Particles
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 – 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.2.5. Suture Materials
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 – 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 – 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 – 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 – 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 – 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 – 2030
9.2.6. Others
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 – 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 – 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 – 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 – 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 – 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Embolization Agents
10. Global Embolization Therapy Market Analysis
and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
10.2.1. Hepatocellular Carcinoma
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 – 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1.
North
America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2.
Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia
Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4.
Middle
East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5.
Latin
America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Neuroendocrine Tumor
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 – 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Liver Cancer
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 – 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Kidney Cancer
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.4.3.
Market
Forecast, 2022 – 2030
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1.
North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2.
Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3.
Asia
Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4.
Middle
East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5.
Latin
America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.2.5. Breast Cancer metastases
10.2.5.1.
Definition
10.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.5.3.
Market
Forecast, 2022 – 2030
10.2.5.4.
Compound
Annual Growth Rate (CAGR)
10.2.5.5.
Regional
Bifurcation
10.2.5.5.1.
North
America
10.2.5.5.1.1. Market Estimation, 2015 - 2021
10.2.5.5.1.2. Market Forecast, 2022 – 2030
10.2.5.5.2.
Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2021
10.2.5.5.2.2. Market Forecast, 2022 – 2030
10.2.5.5.3.
Asia
Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2021
10.2.5.5.3.2. Market Forecast, 2022 – 2030
10.2.5.5.4.
Middle
East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2021
10.2.5.5.4.2. Market Forecast, 2022 – 2030
10.2.5.5.5.
Latin
America
10.2.5.5.5.1. Market Estimation, 2015 - 2021
10.2.5.5.5.2. Market Forecast, 2022 – 2030
10.2.6. Uterine Fibroids
10.2.6.1.
Definition
10.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.6.3.
Market
Forecast, 2022 – 2030
10.2.6.4.
Compound
Annual Growth Rate (CAGR)
10.2.6.5.
Regional
Bifurcation
10.2.6.5.1.
North
America
10.2.6.5.1.1. Market Estimation, 2015 - 2021
10.2.6.5.1.2. Market Forecast, 2022 – 2030
10.2.6.5.2.
Europe
10.2.6.5.2.1. Market Estimation, 2015 - 2021
10.2.6.5.2.2. Market Forecast, 2022 – 2030
10.2.6.5.3.
Asia
Pacific
10.2.6.5.3.1. Market Estimation, 2015 - 2021
10.2.6.5.3.2. Market Forecast, 2022 – 2030
10.2.6.5.4.
Middle
East and Africa
10.2.6.5.4.1. Market Estimation, 2015 - 2021
10.2.6.5.4.2. Market Forecast, 2022 – 2030
10.2.6.5.5.
Latin
America
10.2.6.5.5.1. Market Estimation, 2015 - 2021
10.2.6.5.5.2. Market Forecast, 2022 – 2030
10.2.7. Others
10.2.7.1.
Definition
10.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.7.3.
Market
Forecast, 2022 – 2030
10.2.7.4.
Compound
Annual Growth Rate (CAGR)
10.2.7.5.
Regional
Bifurcation
10.2.7.5.1.
North
America
10.2.7.5.1.1. Market Estimation, 2015 - 2021
10.2.7.5.1.2. Market Forecast, 2022 – 2030
10.2.7.5.2.
Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2021
10.2.7.5.2.2. Market Forecast, 2022 – 2030
10.2.7.5.3.
Asia
Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2021
10.2.7.5.3.2. Market Forecast, 2022 – 2030
10.2.7.5.4.
Middle
East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2021
10.2.7.5.4.2. Market Forecast, 2022 – 2030
10.2.7.5.5.
Latin
America
10.2.7.5.5.1. Market Estimation, 2015 - 2021
10.2.7.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Application
11. Global Embolization Therapy Market Analysis
and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By End Use
11.2.1. Hospitals and Clinics
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 – 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 – 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 – 2030
11.2.2. Specialty Clinics
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 – 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 – 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 – 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 – 2030
11.2.3. Research Institutions
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 – 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 – 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 – 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 – 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 – 2030
11.2.3.5.5.
Latin
America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 – 2030
11.2.4. Others
11.2.4.1.
Definition
11.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.4.3.
Market
Forecast, 2022 – 2030
11.2.4.4.
Compound
Annual Growth Rate (CAGR)
11.2.4.5.
Regional
Bifurcation
11.2.4.5.1.
North
America
11.2.4.5.1.1. Market Estimation, 2015 - 2021
11.2.4.5.1.2. Market Forecast, 2022 – 2030
11.2.4.5.2.
Europe
11.2.4.5.2.1. Market Estimation, 2015 - 2021
11.2.4.5.2.2. Market Forecast, 2022 – 2030
11.2.4.5.3.
Asia
Pacific
11.2.4.5.3.1. Market Estimation, 2015 - 2021
11.2.4.5.3.2. Market Forecast, 2022 – 2030
11.2.4.5.4.
Middle
East and Africa
11.2.4.5.4.1. Market Estimation, 2015 - 2021
11.2.4.5.4.2. Market Forecast, 2022 – 2030
11.2.4.5.5.
Latin
America
11.2.4.5.5.1. Market Estimation, 2015 - 2021
11.2.4.5.5.2. Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1. By End Use
12. North America Embolization Therapy Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.1.1. North America Embolization Therapy Market
Revenue (US$ Mn)
12.2. North America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapy Procedure
12.2.1. Radioembolization
12.2.1.1.
Transarterial
Radioembolization (TARE)
12.2.1.2.
Selective
Internal Radiation Therapy (TARE)
12.2.2. Blandembolization
12.2.3. Chemoembolization
12.3. North America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Embolization Agents
12.3.1. Organic
12.3.2. Coils
12.3.3. Plugs and Balloons
12.3.4. Beads and Particles
12.3.5. Suture Materials
12.3.6. Others
12.4. North America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
12.4.1. Hepatocellular Carcinoma
12.4.2. Neuroendocrine Tumor
12.4.3. Liver Cancer
12.4.4. Kidney Cancer
12.4.5. Breast Cancer metastases
12.4.6. Uterine Fibroids
12.4.7. Others
12.5. North America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By End Use
12.5.1. Hospitals and Clinics
12.5.2. Specialty Clinics
12.5.3. Research Institutions
12.5.4. Others
12.6. North America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
12.6.1.1.1.
Radioembolization
12.6.1.1.1.1. Transarterial Radioembolization (TARE)
12.6.1.1.1.2. Selective Internal Radiation Therapy (TARE)
12.6.1.1.2.
Blandembolization
12.6.1.1.3.
Chemoembolization
12.6.1.2.
U.S
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
12.6.1.2.1.
Organic
12.6.1.2.2.
Coils
12.6.1.2.3.
Plugs
and Balloons
12.6.1.2.4.
Beads
and Particles
12.6.1.2.5.
Suture
Materials
12.6.1.2.6.
Others
12.6.1.3.
U.S
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.3.1.
Hepatocellular
Carcinoma
12.6.1.3.2.
Neuroendocrine
Tumor
12.6.1.3.3.
Liver
Cancer
12.6.1.3.4.
Kidney
Cancer
12.6.1.3.5.
Breast
Cancer metastases
12.6.1.3.6.
Uterine
Fibroids
12.6.1.3.7.
Others
12.6.1.4.
U.S
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
12.6.1.4.1.
Hospitals
and Clinics
12.6.1.4.2.
Specialty
Clinics
12.6.1.4.3.
Research
Institutions
12.6.1.4.4.
Others
12.6.2. Canada
12.6.2.1.
Canada
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
12.6.2.1.1.
Radioembolization
12.6.2.1.1.1. Transarterial Radioembolization (TARE)
12.6.2.1.1.2. Selective Internal Radiation Therapy (TARE)
12.6.2.1.2.
Blandembolization
12.6.2.1.3.
Chemoembolization
12.6.2.2.
Canada
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
12.6.2.2.1.
Organic
12.6.2.2.2.
Coils
12.6.2.2.3.
Plugs
and Balloons
12.6.2.2.4.
Beads
and Particles
12.6.2.2.5.
Suture
Materials
12.6.2.2.6.
Others
12.6.2.3.
Canada
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.3.1.
Hepatocellular
Carcinoma
12.6.2.3.2.
Neuroendocrine
Tumor
12.6.2.3.3.
Liver
Cancer
12.6.2.3.4.
Kidney
Cancer
12.6.2.3.5.
Breast
Cancer metastases
12.6.2.3.6.
Uterine
Fibroids
12.6.2.3.7.
Others
12.6.2.4.
Canada
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
12.6.2.4.1.
Hospitals
and Clinics
12.6.2.4.2.
Specialty
Clinics
12.6.2.4.3.
Research
Institutions
12.6.2.4.4.
Others
12.6.3. Mexico
12.6.3.1.
Mexico
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
12.6.3.1.1.
Radioembolization
12.6.3.1.1.1. Transarterial Radioembolization (TARE)
12.6.3.1.1.2. Selective Internal Radiation Therapy (TARE)
12.6.3.1.2.
Blandembolization
12.6.3.1.3.
Chemoembolization
12.6.3.2.
Mexico
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
12.6.3.2.1.
Organic
12.6.3.2.2.
Coils
12.6.3.2.3.
Plugs
and Balloons
12.6.3.2.4.
Beads
and Particles
12.6.3.2.5.
Suture
Materials
12.6.3.2.6.
Others
12.6.3.3.
Mexico
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.3.1.
Hepatocellular
Carcinoma
12.6.3.3.2.
Neuroendocrine
Tumor
12.6.3.3.3.
Liver
Cancer
12.6.3.3.4.
Kidney
Cancer
12.6.3.3.5.
Breast
Cancer metastases
12.6.3.3.6.
Uterine
Fibroids
12.6.3.3.7.
Others
12.6.3.4.
Mexico
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
12.6.3.4.1.
Hospitals
and Clinics
12.6.3.4.2.
Specialty
Clinics
12.6.3.4.3.
Research
Institutions
12.6.3.4.4.
Others
12.6.4. Rest of North America
12.6.4.1.
Rest of
North America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Procedure
12.6.4.1.1.
Radioembolization
12.6.4.1.1.1. Transarterial Radioembolization (TARE)
12.6.4.1.1.2. Selective Internal Radiation Therapy (TARE)
12.6.4.1.2.
Blandembolization
12.6.4.1.3.
Chemoembolization
12.6.4.2.
Rest of
North America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
12.6.4.2.1.
Organic
12.6.4.2.2.
Coils
12.6.4.2.3.
Plugs
and Balloons
12.6.4.2.4.
Beads
and Particles
12.6.4.2.5.
Suture
Materials
12.6.4.2.6.
Others
12.6.4.3.
Rest of
North America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
12.6.4.3.1.
Hepatocellular
Carcinoma
12.6.4.3.2.
Neuroendocrine
Tumor
12.6.4.3.3.
Liver
Cancer
12.6.4.3.4.
Kidney
Cancer
12.6.4.3.5.
Breast
Cancer metastases
12.6.4.3.6.
Uterine
Fibroids
12.6.4.3.7.
Others
12.6.4.4.
Rest of
North America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
End Use
12.6.4.4.1.
Hospitals
and Clinics
12.6.4.4.2.
Specialty
Clinics
12.6.4.4.3.
Research
Institutions
12.6.4.4.4.
Others
12.7. Key Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Therapy Procedure
12.7.3. By Embolization Agents
12.7.4. By Application
12.7.5. By End Use
13. Europe Embolization Therapy Market Analysis
and Forecasts, 2022 – 2030
13.1. Overview
13.1.1. Europe Embolization Therapy Market Revenue
(US$ Mn)
13.2. Europe Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapy Procedure
13.2.1. Radioembolization
13.2.1.1.
Transarterial
Radioembolization (TARE)
13.2.1.2.
Selective
Internal Radiation Therapy (TARE)
13.2.2. Blandembolization
13.2.3. Chemoembolization
13.3. Europe Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Embolization Agents
13.3.1. Organic
13.3.2. Coils
13.3.3. Plugs and Balloons
13.3.4. Beads and Particles
13.3.5. Suture Materials
13.3.6. Others
13.4. Europe Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Application
13.4.1. Hepatocellular Carcinoma
13.4.2. Neuroendocrine Tumor
13.4.3. Liver Cancer
13.4.4. Kidney Cancer
13.4.5. Breast Cancer metastases
13.4.6. Uterine Fibroids
13.4.7. Others
13.5. Europe Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By End Use
13.5.1. Hospitals and Clinics
13.5.2. Specialty Clinics
13.5.3. Research Institutions
13.5.4. Others
13.6. Europe Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1.
France
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.1.1.1.
Radioembolization
13.6.1.1.1.1. Transarterial Radioembolization (TARE)
13.6.1.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.1.1.2.
Blandembolization
13.6.1.1.3.
Chemoembolization
13.6.1.2.
France
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
13.6.1.2.1.
Organic
13.6.1.2.2.
Coils
13.6.1.2.3.
Plugs
and Balloons
13.6.1.2.4.
Beads
and Particles
13.6.1.2.5.
Suture
Materials
13.6.1.2.6.
Others
13.6.1.3.
France
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.3.1.
Hepatocellular
Carcinoma
13.6.1.3.2.
Neuroendocrine
Tumor
13.6.1.3.3.
Liver
Cancer
13.6.1.3.4.
Kidney
Cancer
13.6.1.3.5.
Breast
Cancer metastases
13.6.1.3.6.
Uterine
Fibroids
13.6.1.3.7.
Others
13.6.1.4.
France
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.1.4.1.
Hospitals
and Clinics
13.6.1.4.2.
Specialty
Clinics
13.6.1.4.3.
Research
Institutions
13.6.1.4.4.
Others
13.6.2. The UK
13.6.2.1.
The UK
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.2.1.1.
Radioembolization
13.6.2.1.1.1. Transarterial Radioembolization (TARE)
13.6.2.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.2.1.2.
Blandembolization
13.6.2.1.3.
Chemoembolization
13.6.2.2.
The UK
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
13.6.2.2.1.
Organic
13.6.2.2.2.
Coils
13.6.2.2.3.
Plugs
and Balloons
13.6.2.2.4.
Beads
and Particles
13.6.2.2.5.
Suture
Materials
13.6.2.2.6.
Others
13.6.2.3.
The UK
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.3.1.
Hepatocellular
Carcinoma
13.6.2.3.2.
Neuroendocrine
Tumor
13.6.2.3.3.
Liver
Cancer
13.6.2.3.4.
Kidney
Cancer
13.6.2.3.5.
Breast
Cancer metastases
13.6.2.3.6.
Uterine Fibroids
13.6.2.3.7.
Others
13.6.2.4.
The UK
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.2.4.1.
Hospitals
and Clinics
13.6.2.4.2.
Specialty
Clinics
13.6.2.4.3.
Research
Institutions
13.6.2.4.4.
Others
13.6.3. Spain
13.6.3.1.
Spain
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.3.1.1.
Radioembolization
13.6.3.1.1.1. Transarterial Radioembolization (TARE)
13.6.3.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.3.1.2.
Blandembolization
13.6.3.1.3.
Chemoembolization
13.6.3.2.
Spain
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
13.6.3.2.1.
Organic
13.6.3.2.2.
Coils
13.6.3.2.3.
Plugs
and Balloons
13.6.3.2.4.
Beads
and Particles
13.6.3.2.5.
Suture
Materials
13.6.3.2.6.
Others
13.6.3.3.
Spain
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.3.1.
Hepatocellular
Carcinoma
13.6.3.3.2.
Neuroendocrine
Tumor
13.6.3.3.3.
Liver
Cancer
13.6.3.3.4.
Kidney
Cancer
13.6.3.3.5.
Breast
Cancer metastases
13.6.3.3.6.
Uterine
Fibroids
13.6.3.3.7.
Others
13.6.3.4.
Spain Embolization
Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.3.4.1.
Hospitals
and Clinics
13.6.3.4.2.
Specialty
Clinics
13.6.3.4.3.
Research
Institutions
13.6.3.4.4.
Others
13.6.4. Germany
13.6.4.1.
Germany
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.4.1.1.
Radioembolization
13.6.4.1.1.1. Transarterial Radioembolization (TARE)
13.6.4.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.4.1.2.
Blandembolization
13.6.4.1.3.
Chemoembolization
13.6.4.2.
Germany
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
13.6.4.2.1.
Organic
13.6.4.2.2.
Coils
13.6.4.2.3.
Plugs
and Balloons
13.6.4.2.4.
Beads
and Particles
13.6.4.2.5.
Suture
Materials
13.6.4.2.6.
Others
13.6.4.3.
Germany
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.3.1.
Hepatocellular
Carcinoma
13.6.4.3.2.
Neuroendocrine
Tumor
13.6.4.3.3.
Liver
Cancer
13.6.4.3.4.
Kidney
Cancer
13.6.4.3.5.
Breast
Cancer metastases
13.6.4.3.6.
Uterine
Fibroids
13.6.4.3.7.
Others
13.6.4.4.
Germany
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.4.4.1.
Hospitals
and Clinics
13.6.4.4.2.
Specialty
Clinics
13.6.4.4.3.
Research
Institutions
13.6.4.4.4.
Others
13.6.5. Italy
13.6.5.1.
Italy
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.5.1.1.
Radioembolization
13.6.5.1.1.1. Transarterial Radioembolization (TARE)
13.6.5.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.5.1.2.
Blandembolization
13.6.5.1.3.
Chemoembolization
13.6.5.2.
Italy
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
13.6.5.2.1.
Organic
13.6.5.2.2.
Coils
13.6.5.2.3.
Plugs
and Balloons
13.6.5.2.4.
Beads
and Particles
13.6.5.2.5.
Suture
Materials
13.6.5.2.6.
Others
13.6.5.3.
Italy
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.3.1.
Hepatocellular
Carcinoma
13.6.5.3.2.
Neuroendocrine
Tumor
13.6.5.3.3.
Liver
Cancer
13.6.5.3.4.
Kidney
Cancer
13.6.5.3.5.
Breast
Cancer metastases
13.6.5.3.6.
Uterine
Fibroids
13.6.5.3.7.
Others
13.6.5.4.
Italy
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.5.4.1.
Hospitals
and Clinics
13.6.5.4.2.
Specialty
Clinics
13.6.5.4.3.
Research
Institutions
13.6.5.4.4.
Others
13.6.6. Nordic Countries
13.6.6.1.
Nordic
Countries Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Procedure
13.6.6.1.1.
Radioembolization
13.6.6.1.1.1. Transarterial Radioembolization (TARE)
13.6.6.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.6.1.2.
Blandembolization
13.6.6.1.3.
Chemoembolization
13.6.6.2.
Nordic
Countries Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
13.6.6.2.1.
Organic
13.6.6.2.2.
Coils
13.6.6.2.3.
Plugs
and Balloons
13.6.6.2.4.
Beads
and Particles
13.6.6.2.5.
Suture
Materials
13.6.6.2.6.
Others
13.6.6.3.
Nordic
Countries Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.6.3.1.
Hepatocellular
Carcinoma
13.6.6.3.2.
Neuroendocrine
Tumor
13.6.6.3.3.
Liver
Cancer
13.6.6.3.4.
Kidney
Cancer
13.6.6.3.5.
Breast
Cancer metastases
13.6.6.3.6.
Uterine
Fibroids
13.6.6.3.7.
Others
13.6.6.4.
Nordic Countries
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.6.4.1.
Hospitals
and Clinics
13.6.6.4.2.
Specialty
Clinics
13.6.6.4.3.
Research
Institutions
13.6.6.4.4.
Others
13.6.6.5.
Nordic
Countries Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux
Union Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.7.1.1.
Radioembolization
13.6.7.1.1.1. Transarterial Radioembolization (TARE)
13.6.7.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.7.1.2.
Blandembolization
13.6.7.1.3.
Chemoembolization
13.6.7.2.
Benelux
Union Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
13.6.7.2.1.
Organic
13.6.7.2.2.
Coils
13.6.7.2.3.
Plugs
and Balloons
13.6.7.2.4.
Beads
and Particles
13.6.7.2.5.
Suture
Materials
13.6.7.2.6.
Others
13.6.7.3.
Benelux
Union Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.7.3.1.
Hepatocellular
Carcinoma
13.6.7.3.2.
Neuroendocrine
Tumor
13.6.7.3.3.
Liver
Cancer
13.6.7.3.4.
Kidney
Cancer
13.6.7.3.5.
Breast
Cancer metastases
13.6.7.3.6.
Uterine
Fibroids
13.6.7.3.7.
Others
13.6.7.4.
Benelux
Union Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.7.4.1.
Hospitals
and Clinics
13.6.7.4.2.
Specialty
Clinics
13.6.7.4.3.
Research
Institutions
13.6.7.4.4.
Others
13.6.7.5.
Benelux
Union Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The
Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of
Europe Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
13.6.8.1.1.
Radioembolization
13.6.8.1.1.1. Transarterial Radioembolization (TARE)
13.6.8.1.1.2. Selective Internal Radiation Therapy (TARE)
13.6.8.1.2.
Blandembolization
13.6.8.1.3.
Chemoembolization
13.6.8.2.
Rest of
Europe Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
13.6.8.2.1.
Organic
13.6.8.2.2.
Coils
13.6.8.2.3.
Plugs
and Balloons
13.6.8.2.4.
Beads
and Particles
13.6.8.2.5.
Suture
Materials
13.6.8.2.6.
Others
13.6.8.3.
Rest of
Europe Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
13.6.8.3.1.
Hepatocellular
Carcinoma
13.6.8.3.2.
Neuroendocrine
Tumor
13.6.8.3.3.
Liver
Cancer
13.6.8.3.4.
Kidney
Cancer
13.6.8.3.5.
Breast
Cancer metastases
13.6.8.3.6.
Uterine
Fibroids
13.6.8.3.7.
Others
13.6.8.4.
Rest of
Europe Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.8.4.1.
Hospitals
and Clinics
13.6.8.4.2.
Specialty
Clinics
13.6.8.4.3.
Research
Institutions
13.6.8.4.4.
Others
13.7. Key Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Therapy Procedure
13.7.3. By Embolization Agents
13.7.4. By Application
13.7.5. By End Use
14. Asia Pacific Embolization Therapy Market
Analysis and Forecasts, 2022 – 2030
14.1. Overview
14.1.1. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn)
14.2. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Therapy Procedure
14.2.1. Radioembolization
14.2.1.1.
Transarterial
Radioembolization (TARE)
14.2.1.2.
Selective
Internal Radiation Therapy (TARE)
14.2.2. Blandembolization
14.2.3. Chemoembolization
14.3. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Embolization Agents
14.3.1. Organic
14.3.2. Coils
14.3.3. Plugs and Balloons
14.3.4. Beads and Particles
14.3.5. Suture Materials
14.3.6. Others
14.4. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
14.4.1. Hepatocellular Carcinoma
14.4.2. Neuroendocrine Tumor
14.4.3. Liver Cancer
14.4.4. Kidney Cancer
14.4.5. Breast Cancer metastases
14.4.6. Uterine Fibroids
14.4.7. Others
14.5. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By End Use
14.5.1. Hospitals and Clinics
14.5.2. Specialty Clinics
14.5.3. Research Institutions
14.5.4. Others
14.6. Asia Pacific Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.1.1.1.
Radioembolization
14.6.1.1.1.1. Transarterial Radioembolization (TARE)
14.6.1.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.1.1.2.
Blandembolization
14.6.1.1.3.
Chemoembolization
14.6.1.2.
China
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
14.6.1.2.1.
Organic
14.6.1.2.2.
Coils
14.6.1.2.3.
Plugs
and Balloons
14.6.1.2.4.
Beads
and Particles
14.6.1.2.5.
Suture
Materials
14.6.1.2.6.
Others
14.6.1.3.
China
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.3.1.
Hepatocellular
Carcinoma
14.6.1.3.2.
Neuroendocrine
Tumor
14.6.1.3.3.
Liver
Cancer
14.6.1.3.4.
Kidney
Cancer
14.6.1.3.5.
Breast
Cancer metastases
14.6.1.3.6.
Uterine
Fibroids
14.6.1.3.7.
Others
14.6.1.4.
China
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.1.4.1.
Hospitals
and Clinics
14.6.1.4.2.
Specialty
Clinics
14.6.1.4.3.
Research
Institutions
14.6.1.4.4.
Others
14.6.2. Japan
14.6.2.1.
Japan
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.2.1.1.
Radioembolization
14.6.2.1.1.1. Transarterial Radioembolization (TARE)
14.6.2.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.2.1.2.
Blandembolization
14.6.2.1.3.
Chemoembolization
14.6.2.2.
Japan
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
14.6.2.2.1.
Organic
14.6.2.2.2.
Coils
14.6.2.2.3.
Plugs
and Balloons
14.6.2.2.4.
Beads
and Particles
14.6.2.2.5.
Suture
Materials
14.6.2.2.6.
Others
14.6.2.3.
Japan
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.3.1.
Hepatocellular
Carcinoma
14.6.2.3.2.
Neuroendocrine
Tumor
14.6.2.3.3.
Liver
Cancer
14.6.2.3.4.
Kidney
Cancer
14.6.2.3.5.
Breast
Cancer metastases
14.6.2.3.6.
Uterine
Fibroids
14.6.2.3.7.
Others
14.6.2.4.
Japan
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.2.4.1.
Hospitals
and Clinics
14.6.2.4.2.
Specialty
Clinics
14.6.2.4.3.
Research
Institutions
14.6.2.4.4.
Others
14.6.3. India
14.6.3.1.
India
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.3.1.1.
Radioembolization
14.6.3.1.1.1. Transarterial Radioembolization (TARE)
14.6.3.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.3.1.2.
Blandembolization
14.6.3.1.3.
Chemoembolization
14.6.3.2.
India
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
14.6.3.2.1.
Organic
14.6.3.2.2.
Coils
14.6.3.2.3.
Plugs
and Balloons
14.6.3.2.4.
Beads
and Particles
14.6.3.2.5.
Suture
Materials
14.6.3.2.6.
Others
14.6.3.3.
India
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.3.1.
Hepatocellular
Carcinoma
14.6.3.3.2.
Neuroendocrine
Tumor
14.6.3.3.3.
Liver
Cancer
14.6.3.3.4.
Kidney
Cancer
14.6.3.3.5.
Breast
Cancer metastases
14.6.3.3.6.
Uterine
Fibroids
14.6.3.3.7.
Others
14.6.3.4.
India
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.3.4.1.
Hospitals
and Clinics
14.6.3.4.2.
Specialty
Clinics
14.6.3.4.3.
Research
Institutions
14.6.3.4.4.
Others
14.6.4. New Zealand
14.6.4.1.
New
Zealand Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.4.1.1.
Radioembolization
14.6.4.1.1.1. Transarterial Radioembolization (TARE)
14.6.4.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.4.1.2.
Blandembolization
14.6.4.1.3.
Chemoembolization
14.6.4.2.
New
Zealand Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
14.6.4.2.1.
Organic
14.6.4.2.2.
Coils
14.6.4.2.3.
Plugs
and Balloons
14.6.4.2.4.
Beads
and Particles
14.6.4.2.5.
Suture
Materials
14.6.4.2.6.
Others
14.6.4.3.
New
Zealand Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.4.3.1.
Hepatocellular
Carcinoma
14.6.4.3.2.
Neuroendocrine
Tumor
14.6.4.3.3.
Liver
Cancer
14.6.4.3.4.
Kidney
Cancer
14.6.4.3.5.
Breast
Cancer metastases
14.6.4.3.6.
Uterine
Fibroids
14.6.4.3.7.
Others
14.6.4.4.
New
Zealand Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.4.4.1.
Hospitals
and Clinics
14.6.4.4.2.
Specialty
Clinics
14.6.4.4.3.
Research
Institutions
14.6.4.4.4.
Others
14.6.5. Australia
14.6.5.1.
Australia
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.5.1.1.
Radioembolization
14.6.5.1.1.1. Transarterial Radioembolization (TARE)
14.6.5.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.5.1.2.
Blandembolization
14.6.5.1.3.
Chemoembolization
14.6.5.2.
Australia
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
14.6.5.2.1.
Organic
14.6.5.2.2.
Coils
14.6.5.2.3.
Plugs
and Balloons
14.6.5.2.4.
Beads
and Particles
14.6.5.2.5.
Suture
Materials
14.6.5.2.6.
Others
14.6.5.3.
Australia
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.3.1.
Hepatocellular
Carcinoma
14.6.5.3.2.
Neuroendocrine
Tumor
14.6.5.3.3.
Liver
Cancer
14.6.5.3.4.
Kidney
Cancer
14.6.5.3.5.
Breast
Cancer metastases
14.6.5.3.6.
Uterine
Fibroids
14.6.5.3.7.
Others
14.6.5.4.
Australia
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.5.4.1.
Hospitals
and Clinics
14.6.5.4.2.
Specialty
Clinics
14.6.5.4.3.
Research
Institutions
14.6.5.4.4.
Others
14.6.6. South Korea
14.6.6.1.
South
Korea Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.6.1.1.
Radioembolization
14.6.6.1.1.1. Transarterial Radioembolization (TARE)
14.6.6.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.6.1.2.
Blandembolization
14.6.6.1.3.
Chemoembolization
14.6.6.2.
South
Korea Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
14.6.6.2.1.
Organic
14.6.6.2.2.
Coils
14.6.6.2.3.
Plugs
and Balloons
14.6.6.2.4.
Beads
and Particles
14.6.6.2.5.
Suture
Materials
14.6.6.2.6.
Others
14.6.6.3.
South
Korea Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.6.3.1.
Hepatocellular
Carcinoma
14.6.6.3.2.
Neuroendocrine
Tumor
14.6.6.3.3.
Liver
Cancer
14.6.6.3.4.
Kidney
Cancer
14.6.6.3.5.
Breast
Cancer metastases
14.6.6.3.6.
Uterine
Fibroids
14.6.6.3.7.
Others
14.6.6.4.
South
Korea Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.6.4.1.
Hospitals
and Clinics
14.6.6.4.2.
Specialty
Clinics
14.6.6.4.3.
Research
Institutions
14.6.6.4.4.
Others
14.6.7. Southeast Asia
14.6.7.1.
Southeast
Asia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
14.6.7.1.1.
Radioembolization
14.6.7.1.1.1. Transarterial Radioembolization (TARE)
14.6.7.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.7.1.2.
Blandembolization
14.6.7.1.3.
Chemoembolization
14.6.7.2.
Southeast
Asia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
14.6.7.2.1.
Organic
14.6.7.2.2.
Coils
14.6.7.2.3.
Plugs
and Balloons
14.6.7.2.4.
Beads
and Particles
14.6.7.2.5.
Suture
Materials
14.6.7.2.6.
Others
14.6.7.3.
Southeast
Asia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
14.6.7.3.1.
Hepatocellular
Carcinoma
14.6.7.3.2.
Neuroendocrine
Tumor
14.6.7.3.3.
Liver
Cancer
14.6.7.3.4.
Kidney
Cancer
14.6.7.3.5.
Breast
Cancer metastases
14.6.7.3.6.
Uterine
Fibroids
14.6.7.3.7.
Others
14.6.7.4.
Southeast
Asia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.7.4.1.
Hospitals
and Clinics
14.6.7.4.2.
Specialty
Clinics
14.6.7.4.3.
Research
Institutions
14.6.7.4.4.
Others
14.6.7.5.
Southeast
Asia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of
Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of
Asia Pacific Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Procedure
14.6.8.1.1.
Radioembolization
14.6.8.1.1.1. Transarterial Radioembolization (TARE)
14.6.8.1.1.2. Selective Internal Radiation Therapy (TARE)
14.6.8.1.2.
Blandembolization
14.6.8.1.3.
Chemoembolization
14.6.8.2.
Rest of
Asia Pacific Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
14.6.8.2.1.
Organic
14.6.8.2.2.
Coils
14.6.8.2.3.
Plugs
and Balloons
14.6.8.2.4.
Beads
and Particles
14.6.8.2.5.
Suture
Materials
14.6.8.2.6.
Others
14.6.8.3.
Rest of
Asia Pacific Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
14.6.8.3.1.
Hepatocellular
Carcinoma
14.6.8.3.2.
Neuroendocrine
Tumor
14.6.8.3.3.
Liver Cancer
14.6.8.3.4.
Kidney
Cancer
14.6.8.3.5.
Breast
Cancer metastases
14.6.8.3.6.
Uterine
Fibroids
14.6.8.3.7.
Others
14.6.8.4.
Rest of
Asia Pacific Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End
Use
14.6.8.4.1.
Hospitals
and Clinics
14.6.8.4.2.
Specialty
Clinics
14.6.8.4.3.
Research
Institutions
14.6.8.4.4.
Others
14.7. Key Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Therapy Procedure
14.7.3. By Embolization Agents
14.7.4. By Application
14.7.5. By End Use
15. Middle East and Africa Embolization Therapy
Market Analysis and Forecasts, 2022 – 2030
15.1. Overview
15.1.1. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn)
15.2. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn) and Forecasts, By Therapy Procedure
15.2.1. Radioembolization
15.2.1.1.
Transarterial
Radioembolization (TARE)
15.2.1.2.
Selective
Internal Radiation Therapy (TARE)
15.2.2. Blandembolization
15.2.3. Chemoembolization
15.3. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn) and Forecasts, By Embolization Agents
15.3.1. Organic
15.3.2. Coils
15.3.3. Plugs and Balloons
15.3.4. Beads and Particles
15.3.5. Suture Materials
15.3.6. Others
15.4. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1. Hepatocellular Carcinoma
15.4.2. Neuroendocrine Tumor
15.4.3. Liver Cancer
15.4.4. Kidney Cancer
15.4.5. Breast Cancer metastases
15.4.6. Uterine Fibroids
15.4.7. Others
15.5. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn) and Forecasts, By End Use
15.5.1. Hospitals and Clinics
15.5.2. Specialty Clinics
15.5.3. Research Institutions
15.5.4. Others
15.6. Middle East and Africa Embolization Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi
Arabia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
15.6.1.1.1.
Radioembolization
15.6.1.1.1.1. Transarterial Radioembolization (TARE)
15.6.1.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.1.1.2.
Blandembolization
15.6.1.1.3.
Chemoembolization
15.6.1.2.
Saudi
Arabia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
15.6.1.2.1.
Organic
15.6.1.2.2.
Coils
15.6.1.2.3.
Plugs
and Balloons
15.6.1.2.4.
Beads
and Particles
15.6.1.2.5.
Suture
Materials
15.6.1.2.6.
Others
15.6.1.3.
Saudi
Arabia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.1.3.1.
Hepatocellular
Carcinoma
15.6.1.3.2.
Neuroendocrine
Tumor
15.6.1.3.3.
Liver
Cancer
15.6.1.3.4.
Kidney
Cancer
15.6.1.3.5.
Breast
Cancer metastases
15.6.1.3.6.
Uterine
Fibroids
15.6.1.3.7.
Others
15.6.1.4.
Saudi
Arabia Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.1.4.1.
Hospitals
and Clinics
15.6.1.4.2.
Specialty
Clinics
15.6.1.4.3.
Research
Institutions
15.6.1.4.4.
Others
15.6.2. UAE
15.6.2.1.
UAE
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
15.6.2.1.1.
Radioembolization
15.6.2.1.1.1. Transarterial Radioembolization (TARE)
15.6.2.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.2.1.2.
Blandembolization
15.6.2.1.3.
Chemoembolization
15.6.2.2.
UAE
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
15.6.2.2.1.
Organic
15.6.2.2.2.
Coils
15.6.2.2.3.
Plugs
and Balloons
15.6.2.2.4.
Beads and
Particles
15.6.2.2.5.
Suture
Materials
15.6.2.2.6.
Others
15.6.2.3.
UAE
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.3.1.
Hepatocellular
Carcinoma
15.6.2.3.2.
Neuroendocrine
Tumor
15.6.2.3.3.
Liver
Cancer
15.6.2.3.4.
Kidney
Cancer
15.6.2.3.5.
Breast
Cancer metastases
15.6.2.3.6.
Uterine
Fibroids
15.6.2.3.7.
Others
15.6.2.4.
UAE
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.2.4.1.
Hospitals
and Clinics
15.6.2.4.2.
Specialty
Clinics
15.6.2.4.3.
Research
Institutions
15.6.2.4.4.
Others
15.6.3. Egypt
15.6.3.1.
Egypt
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
15.6.3.1.1.
Radioembolization
15.6.3.1.1.1. Transarterial Radioembolization (TARE)
15.6.3.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.3.1.2.
Blandembolization
15.6.3.1.3.
Chemoembolization
15.6.3.2.
Egypt
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
15.6.3.2.1.
Organic
15.6.3.2.2.
Coils
15.6.3.2.3.
Plugs
and Balloons
15.6.3.2.4.
Beads
and Particles
15.6.3.2.5.
Suture
Materials
15.6.3.2.6.
Others
15.6.3.3.
Egypt
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.3.1.
Hepatocellular
Carcinoma
15.6.3.3.2.
Neuroendocrine
Tumor
15.6.3.3.3.
Liver
Cancer
15.6.3.3.4.
Kidney
Cancer
15.6.3.3.5.
Breast
Cancer metastases
15.6.3.3.6.
Uterine
Fibroids
15.6.3.3.7.
Others
15.6.3.4.
Egypt
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.3.4.1.
Hospitals
and Clinics
15.6.3.4.2.
Specialty
Clinics
15.6.3.4.3.
Research
Institutions
15.6.3.4.4.
Others
15.6.4. Kuwait
15.6.4.1.
Kuwait
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
15.6.4.1.1.
Radioembolization
15.6.4.1.1.1. Transarterial Radioembolization (TARE)
15.6.4.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.4.1.2.
Blandembolization
15.6.4.1.3.
Chemoembolization
15.6.4.2.
Kuwait
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
15.6.4.2.1.
Organic
15.6.4.2.2.
Coils
15.6.4.2.3.
Plugs
and Balloons
15.6.4.2.4.
Beads
and Particles
15.6.4.2.5.
Suture
Materials
15.6.4.2.6.
Others
15.6.4.3.
Kuwait
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.3.1.
Hepatocellular
Carcinoma
15.6.4.3.2.
Neuroendocrine
Tumor
15.6.4.3.3.
Liver
Cancer
15.6.4.3.4.
Kidney
Cancer
15.6.4.3.5.
Breast
Cancer metastases
15.6.4.3.6.
Uterine
Fibroids
15.6.4.3.7.
Others
15.6.4.4.
Kuwait
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.4.4.1.
Hospitals
and Clinics
15.6.4.4.2.
Specialty
Clinics
15.6.4.4.3.
Research
Institutions
15.6.4.4.4.
Others
15.6.5. South Africa
15.6.5.1.
South
Africa Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
15.6.5.1.1.
Radioembolization
15.6.5.1.1.1. Transarterial Radioembolization (TARE)
15.6.5.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.5.1.2.
Blandembolization
15.6.5.1.3.
Chemoembolization
15.6.5.2.
South
Africa Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
15.6.5.2.1.
Organic
15.6.5.2.2.
Coils
15.6.5.2.3.
Plugs
and Balloons
15.6.5.2.4.
Beads
and Particles
15.6.5.2.5.
Suture
Materials
15.6.5.2.6.
Others
15.6.5.3.
South
Africa Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
15.6.5.3.1.
Hepatocellular
Carcinoma
15.6.5.3.2.
Neuroendocrine
Tumor
15.6.5.3.3.
Liver
Cancer
15.6.5.3.4.
Kidney
Cancer
15.6.5.3.5.
Breast
Cancer metastases
15.6.5.3.6.
Uterine
Fibroids
15.6.5.3.7.
Others
15.6.5.4.
South
Africa Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.5.4.1.
Hospitals
and Clinics
15.6.5.4.2.
Specialty
Clinics
15.6.5.4.3.
Research
Institutions
15.6.5.4.4.
Others
15.6.6. Rest of Middle East & Africa
15.6.6.1.
Rest of
Middle East & Africa Embolization Therapy Market Revenue (US$ Mn) and
Forecasts, By Therapy Procedure
15.6.6.1.1.
Radioembolization
15.6.6.1.1.1. Transarterial Radioembolization (TARE)
15.6.6.1.1.2. Selective Internal Radiation Therapy (TARE)
15.6.6.1.2.
Blandembolization
15.6.6.1.3.
Chemoembolization
15.6.6.2.
Rest of
Middle East & Africa Embolization Therapy Market Revenue (US$ Mn) and
Forecasts, By Embolization Agents
15.6.6.2.1.
Organic
15.6.6.2.2.
Coils
15.6.6.2.3.
Plugs
and Balloons
15.6.6.2.4.
Beads
and Particles
15.6.6.2.5.
Suture
Materials
15.6.6.2.6.
Others
15.6.6.3.
Rest of
Middle East & Africa Embolization Therapy Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.6.3.1.
Hepatocellular
Carcinoma
15.6.6.3.2.
Neuroendocrine
Tumor
15.6.6.3.3.
Liver
Cancer
15.6.6.3.4.
Kidney
Cancer
15.6.6.3.5.
Breast
Cancer metastases
15.6.6.3.6.
Uterine
Fibroids
15.6.6.3.7.
Others
15.6.6.4.
Rest of
Middle East & Africa Embolization Therapy Market Revenue (US$ Mn) and
Forecasts, By End Use
15.6.6.4.1.
Hospitals
and Clinics
15.6.6.4.2.
Specialty
Clinics
15.6.6.4.3.
Research
Institutions
15.6.6.4.4.
Others
15.7. Key Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Therapy Procedure
15.7.3. By Embolization Agents
15.7.4. By Application
15.7.5. By End Use
16. Latin America Embolization Therapy Market
Analysis and Forecasts, 2022 – 2030
16.1. Overview
16.1.1. Latin America Embolization Therapy Market
Revenue (US$ Mn)
16.2. Latin America Embolization Therapy Market Revenue
(US$ Mn) and Forecasts, By Therapy Procedure
16.2.1. Radioembolization
16.2.1.1.
Transarterial
Radioembolization (TARE)
16.2.1.2.
Selective
Internal Radiation Therapy (TARE)
16.2.2. Blandembolization
16.2.3. Chemoembolization
16.3. Latin America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Embolization Agents
16.3.1. Organic
16.3.2. Coils
16.3.3. Plugs and Balloons
16.3.4. Beads and Particles
16.3.5. Suture Materials
16.3.6. Others
16.4. Latin America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Application
16.4.1. Hepatocellular Carcinoma
16.4.2. Neuroendocrine Tumor
16.4.3. Liver Cancer
16.4.4. Kidney Cancer
16.4.5. Breast Cancer metastases
16.4.6. Uterine Fibroids
16.4.7. Others
16.5. Latin America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By End Use
16.5.1. Hospitals and Clinics
16.5.2. Specialty Clinics
16.5.3. Research Institutions
16.5.4. Others
16.6. Latin America Embolization Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
16.6.1.1.1.
Radioembolization
16.6.1.1.1.1. Transarterial Radioembolization (TARE)
16.6.1.1.1.2. Selective Internal Radiation Therapy (TARE)
16.6.1.1.2.
Blandembolization
16.6.1.1.3.
Chemoembolization
16.6.1.2.
Brazil
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
16.6.1.2.1.
Organic
16.6.1.2.2.
Coils
16.6.1.2.3.
Plugs
and Balloons
16.6.1.2.4.
Beads
and Particles
16.6.1.2.5.
Suture
Materials
16.6.1.2.6.
Others
16.6.1.3.
Brazil
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.3.1.
Hepatocellular
Carcinoma
16.6.1.3.2.
Neuroendocrine
Tumor
16.6.1.3.3.
Liver
Cancer
16.6.1.3.4.
Kidney
Cancer
16.6.1.3.5.
Breast
Cancer metastases
16.6.1.3.6.
Uterine
Fibroids
16.6.1.3.7.
Others
16.6.1.4.
Brazil
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
16.6.1.4.1.
Hospitals
and Clinics
16.6.1.4.2.
Specialty
Clinics
16.6.1.4.3.
Research
Institutions
16.6.1.4.4.
Others
16.6.2. Argentina
16.6.2.1.
Argentina
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Therapy
Procedure
16.6.2.1.1.
Radioembolization
16.6.2.1.1.1. Transarterial Radioembolization (TARE)
16.6.2.1.1.2. Selective Internal Radiation Therapy (TARE)
16.6.2.1.2.
Blandembolization
16.6.2.1.3.
Chemoembolization
16.6.2.2.
Argentina
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Embolization
Agents
16.6.2.2.1.
Organic
16.6.2.2.2.
Coils
16.6.2.2.3.
Plugs
and Balloons
16.6.2.2.4.
Beads
and Particles
16.6.2.2.5.
Suture
Materials
16.6.2.2.6.
Others
16.6.2.3.
Argentina
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.3.1.
Hepatocellular
Carcinoma
16.6.2.3.2.
Neuroendocrine
Tumor
16.6.2.3.3.
Liver
Cancer
16.6.2.3.4.
Kidney
Cancer
16.6.2.3.5.
Breast
Cancer metastases
16.6.2.3.6.
Uterine
Fibroids
16.6.2.3.7.
Others
16.6.2.4.
Argentina
Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By End Use
16.6.2.4.1.
Hospitals
and Clinics
16.6.2.4.2.
Specialty
Clinics
16.6.2.4.3.
Research
Institutions
16.6.2.4.4.
Others
16.6.3. Rest of Latin America
16.6.3.1.
Rest of
Latin America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Therapy Procedure
16.6.3.1.1.
Radioembolization
16.6.3.1.1.1. Transarterial Radioembolization (TARE)
16.6.3.1.1.2. Selective Internal Radiation Therapy (TARE)
16.6.3.1.2.
Blandembolization
16.6.3.1.3.
Chemoembolization
16.6.3.2.
Rest of
Latin America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Embolization Agents
16.6.3.2.1.
Organic
16.6.3.2.2.
Coils
16.6.3.2.3.
Plugs
and Balloons
16.6.3.2.4.
Beads
and Particles
16.6.3.2.5.
Suture
Materials
16.6.3.2.6.
Others
16.6.3.3.
Rest of
Latin America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
Application
16.6.3.3.1.
Hepatocellular
Carcinoma
16.6.3.3.2.
Neuroendocrine
Tumor
16.6.3.3.3.
Liver
Cancer
16.6.3.3.4.
Kidney
Cancer
16.6.3.3.5.
Breast
Cancer metastases
16.6.3.3.6.
Uterine
Fibroids
16.6.3.3.7.
Others
16.6.3.4.
Rest of
Latin America Embolization Therapy Market Revenue (US$ Mn) and Forecasts, By
End Use
16.6.3.4.1.
Hospitals
and Clinics
16.6.3.4.2.
Specialty
Clinics
16.6.3.4.3.
Research
Institutions
16.6.3.4.4.
Others
16.7. Key Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Therapy Procedure
16.7.3. By Embolization Agents
16.7.4. By Application
16.7.5. By End Use
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Market Share Analysis, 2021
17.3. Global Presence and Growth Strategies
17.3.1. Mergers and Acquisitions
17.3.2. Product Launches
17.3.3. Investments Trends
17.3.4. R&D Initiatives
18. Player Profiles
18.1. ABK Biomedical Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. Boston Scientific Corporation
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. BTG International Limited
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Cook Medical
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. EmboMedics
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. IMBIOTECHNOLOGIES LTD.
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Johnson & Johnson Services Inc.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Merit Medical Systems Inc.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Radiology Imaging Associates
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Sirtex Medical Pty Ltd
18.10.1. Company Details
18.10.2. Company Overview
18.10.3. Product Offerings
18.10.4. Key Developments
18.10.5. Financial Analysis
18.10.6. SWOT Analysis
18.10.7. Business Strategies
18.11. Stryker Corporation
18.11.1. Company Details
18.11.2. Company Overview
18.11.3. Product Offerings
18.11.4. Key Developments
18.11.5. Financial Analysis
18.11.6. SWOT Analysis
18.11.7. Business Strategies
18.12. Terumo Corporation
18.12.1. Company Details
18.12.2. Company Overview
18.12.3. Product Offerings
18.12.4. Key Developments
18.12.5. Financial Analysis
18.12.6. SWOT Analysis
18.12.7. Business Strategies
18.13. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.